Coates Laura C
Leeds Inst. of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, UK and Div. of Allergy, Immunology and Rheumatology, Univ. of Rochester Medical Center, USA.
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S70-2. Epub 2015 Oct 15.
Psoriatic arthritis (PsA) is a heterogeneous condition with a myriad of different clinical presentations. It commonly affects the skin and musculoskeletal system causing psoriasis, peripheral arthritis, axial arthritis, enthesitis and dactylitis. Many patients also have related conditions, such as those within the metabolic syndrome and associated spondyloarthritis (SpA) conditions including inflammatory bowel disease and uveitis. Any therapeutic strategy must be tailored to the individual patient, taking into account her/his complete clinical presentation and comorbidities. New treatment recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) provide evidence based recommendations on effective therapies for the management of each different manifestation of PsA, and how treatment may be affected by comorbidities (1). However, the limited evidence comparing different treatment strategies in PsA is recognised as a limitation in these recommendations and further information is detailed below.
银屑病关节炎（PsA）是一种具有多种不同临床表现的异质性疾病。它通常会影响皮肤和肌肉骨骼系统，导致银屑病、外周关节炎、中轴关节炎、附着点炎和指（趾）炎。许多患者还患有相关疾病，如代谢综合征以及包括炎症性肠病和葡萄膜炎在内的相关脊柱关节炎（SpA）疾病。任何治疗策略都必须根据个体患者的情况进行调整，要考虑到其完整的临床表现和合并症。银屑病和银屑病关节炎研究与评估小组（GRAPPA）的新治疗建议提供了基于证据的建议，涉及PsA每种不同表现形式的有效治疗方法，以及合并症可能如何影响治疗（1）。然而，比较PsA不同治疗策略的证据有限，这被认为是这些建议中的一个局限性，更多信息将在下文详述。
